TRUPANION, INC. annual report, FY2023

Business Context and Reporting Period

Trupanion, Inc. provides medical insurance for cats and dogs in the United States, Canada, Continental Europe and Australia through subscription and other business segments. This Form 10-K covers the fiscal year ended December 31, 2023; fourth-quarter results are included for the three months ended December 31, 2023.

Total enrolled pets increased 12% to 1.714 million at year-end; subscription pets increased 14% to 991,426.
Subscription revenue is primarily direct-to-consumer recurring revenue. The other business segment primarily underwrites policies for third parties and generally has lower margins.

Financial Performance and Key Metrics

Metric	FY 2023	FY 2022	Change
Total revenue	$1,108.6 million	$905.2 million	Up 22%
Subscription revenue	$712.9 million	$596.6 million	Up 19%
Other business revenue	$395.7 million	$308.6 million	Up 28%
Operating loss	$40.7 million	$43.0 million	Improved $2.3 million
Net loss	$44.7 million	$44.7 million	Essentially unchanged
Net loss per share	$1.08	$1.10	Improved
Operating cash flow	$18.6 million	$(8.0) million	Improved $26.6 million

Gross margin was approximately 11.8%, compared with approximately 13.5% in 2022, as total cost of revenue increased to 88% of revenue from 87%.
Subscription segment cost of revenue increased to 86% of subscription revenue from 83%, primarily because veterinary invoice expense increased 24%, including a 7% increase in veterinary invoice expense per pet.
New pet acquisition expense declined 14% to $77.4 million, while average pet acquisition cost declined 21% to $228. Subscription monthly average revenue per pet increased 2% to $65.26.
Average monthly retention remained high at 98.49%, but declined from 98.69%. Reported lifetime value of a pet, including fixed expenses, declined to $419 from $641.
Fourth-quarter revenue was $295.9 million, compared with $246.0 million in the prior-year quarter. Fourth-quarter operating income was $0.4 million versus a $9.2 million operating loss, and net loss was $2.2 million versus $9.3 million.
Total stock-based compensation expense was $33.2 million, broadly consistent with $33.4 million in 2022.

Liquidity, Capital and Debt

Cash, cash equivalents and short-term investments totaled $277.2 million at December 31, 2023, including $230.6 million held by insurance entities and $46.6 million outside those entities.
The company had $170.5 million of cash, cash equivalents and restricted cash at year-end, compared with $84.6 million at the end of 2022.
Cash provided by financing activities was $59.1 million, primarily reflecting $60.1 million of net proceeds from the Credit Facility.
Outstanding debt was $128.9 million at year-end, with $135.0 million of term loans issued under a $150.0 million facility. The facility bears floating-rate interest; the stated rate was approximately 10.5% at year-end and substantially all company assets secure the facility.
A 100-basis-point increase in interest rates would increase annual interest expense by approximately $1.3 million.
Insurance entities held $241.3 million of capital surplus, $64.1 million above the estimated $177.2 million risk-based capital requirement. Dividend and capital transfers remain subject to regulatory restrictions.
Management stated that operating cash flow and available borrowings were sufficient to fund operations and capital requirements for the next 12 months, while noting that additional financing may be needed for growth or capital requirements.

Material Changes Versus the Prior Comparable Period

Revenue growth remained strong, but the revenue mix shifted toward the lower-margin other business segment, which represented 36% of total revenue versus 34% in 2022. Subscription revenue declined to 64% of total revenue from 66%.
Veterinary invoice expense increased 28% overall to $831.1 million and rose faster than revenue in the subscription segment, pressuring margins.
General and administrative expense increased 53% to $60.2 million, including executive departure-related stock compensation and a $3.8 million non-recurring settlement related to uncollected premiums from the transition of third-party underwriting.
Technology and development expense declined 15% to $21.4 million as certain previously pre-revenue initiatives began generating revenue.
Operating cash flow improved materially, driven by increased collections, lower acquisition spending and working-capital changes, including a larger reserve for veterinary invoices.
The reserve for veterinary invoices increased to $63.2 million from $43.7 million. The company reported $3.3 million of unfavorable development on prior-year reserves in 2023.

Guidance, Outlook, Risks and Unusual Items

The filing does not provide a clear quantitative full-year 2024 revenue or earnings outlook. Management continues to emphasize membership growth, retention, pricing adjustments, automation of invoice payments, distribution expansion and international growth.
Management targets returning approximately 71% of premiums collected to members in aggregate, subject to pricing, veterinary cost and regulatory conditions.
The company expects portions of the other business segment to roll off beginning in 2025, subject to contractual limitations. Timing and extent are not controlled by Trupanion and could cause revenue and earnings volatility.
Major risks include continued operating losses, rising veterinary costs, reserve estimation risk, lower retention, acquisition-cost volatility, competition, regulatory limits on pricing and capital distributions, foreign exchange exposure, and dependence on veterinarians, Territory Partners and third-party general agents.
One general agent sourced policies representing more than 10% of total revenue, and general-agent-sourced premiums represented 34% of 2023 revenue.
Management concluded that disclosure controls and internal control over financial reporting were not effective at December 31, 2023 because of two material weaknesses: IT general controls over certain subscription systems and controls over transactions processed by an unaffiliated general agent. Ernst & Young issued an adverse opinion on internal control effectiveness but an unqualified opinion on the consolidated financial statements.
The company recorded a $1.7 million credit loss allowance related to its preferred-stock investment in Baystride, a pet-food venture, and continues to carry related strategic investment and lending exposure.
The filing states that cybersecurity threats, including prior incidents, had not materially affected the company and were not reasonably likely to materially affect its business, strategy, operations or financial condition as of the filing date.

Most Important Facts for Investors to Verify

Whether subscription veterinary invoice costs stabilize relative to pricing and whether the targeted value proposition can be maintained.
Whether retention, lifetime value and pet acquisition costs improve or deteriorate as enrollment growth and acquisition channels change.
The timing and financial effect of any roll-off in the other business segment beginning in 2025.
Progress in remediating the two material weaknesses and whether subsequent filings report effective internal controls.
Liquidity available outside regulated insurance entities, compliance with debt covenants and the impact of floating-rate debt.
The adequacy of the $63.2 million veterinary invoice reserve and future reserve development.
The ability of insurance subsidiaries to distribute surplus capital to the parent company and the effect of regulatory capital requirements on growth spending.
Exposure to general-agent concentration, third-party underwriting arrangements, foreign exchange movements and regulatory changes affecting pet insurance and artificial intelligence.